Kornimate/medical-research-clean huggingface dataset:
reliability and validity of the turkish version of caregiver functional use survey (cfus)

Conditions: Cerebral Palsy

Summary: increasing the number of turkish version of the questionnaire evaluating hand use, adding the scales that evaluate the selective movements of the upper limb to the evaluations will increase the variety of evaluation methods. the purpose of this study is to evaluate the validity and reliability of the turkish version of the caregiver functional use survey (cfus)

cfus was designed to assess caregivers' perceptions of how much and how well their child used the involved upper extremity. children's upper extremity functions will be assessed with a jebsen taylor hand function test. their family will be asked to fill the cfus. compare the relationship between jebsen-taylor hand function test and turkish version cfus. investigate the internal consistency of turkish-version of cfus by using cronbach's alpha coefficient.

Eligibility criteria:
inclusion criteria: * ages between 3-15 years * diagnosed as cerebral palsy (hemiplegia) * literate in turkish language and can complete the questionnaire by primer caregiver exclusion criteria: * cannot understand the questionnaire by themselves. * participants had a botulinum toxin injection within the last 6 months * any surgical correction within the last year
effects of omt on interoception

Conditions: Chronic Low Back Pain

Summary: recent evidence suggested that the anterior insula cortex seems to be the main site of interoception. several studies showed an association between change in insula function and interoception, bodily perception and consciousness in subjects with chronic pain. although osteopathic research has been demonstrated to be effective in reducing pain, studies exploring the effect of osteopathy on interoception are lacking. therefore, the aim of the present study is to explore the extent to which osteopathic treatment could modify interoception parameters both measuring brain functional connectivity and clinical questionnaires.


Eligibility criteria:
inclusion criteria: * chronic low back pain * written informed consent signed exclusion criteria: * congenital disease * acute pain * subject below 30 and above 50 * co-morbidities associated with low back pain * surgical patients * cardio-vascular, respiratory, gastro-enteric disease * obese subjects * diabetics * dizziness * subjects into pharmacological prophylaxis * drug addicted subjects * subjects undergoing physiotherapy * subjects with experience in osteopathic treatment

Keywords: osteopathic manipulative treatment interoception
niv prevents post-operative respiratory failure after bariatric surgery

Conditions: Obesity; Postoperative Respiratory Distress

Summary: postoperative non-invasive ventilation (niv) has been proposed as an attractive strategy to reduce morbidity and improve postoperative outcomes in obese subjects undergoing general anesthesia. bariatric patients present a peculiar negative feature; the increased body mass index (bmi) correlates with loss of perioperative functional residual capacity (frc), expiratory reserve volume (erv) and total lung capacity (tlc), decreased up to 50% of preoperative values. the aim of the current randomized trial is to evaluate the efficacy of niv in post-anaesthesia care unit (pacu) in reducing post-extubation acute respiratory failure and the consequent admission in intensive care units (icu) after bibp in obese adult patients.


Eligibility criteria:
inclusion criteria: * morbid obesity * patients undergoing biliointestinal bypass (bibp) exclusion criteria: * patients requiring emergency operation with rapid sequence induction * patients with suspected presence of difficult airway or pre-existing lung impairment * pregnancy * asthma * severe renal dysfunction, * cardiac disease resulting in marked limitation of physical activity, corresponding to nyha class \>ii
cerebral oxygenation and metabolism after reversal of rocuronium: comparison between sugammadex versus neostigmine

Conditions: Supratentorial Brain Tumor Surgery

Summary: cholinesterase inhibitors such as neostigmine and edrophonium have been used to reverse neuromuscular blockade after surgery. however, these drugs have a relatively slow onset and have adverse effects associated with stimulation of muscarinic receptors. in addition, neostigmine cannot be used to reverse profound blockade. anesthetics may exert their effects on various facets of cerebral function such as cerebral metabolic rate (cmro2), cerebral blood flow (cbf), cerebral blood flow-metabolism coupling, intra cranial pressure (icp), autoregulation, vascular response to co2 and brain electrical activity. the net result of all these effects of the anaesthetic agents combined with their systemic effects may prove beneficial or detrimental to an already diseased brain. in neurosurgical patients, clear and rapid recovery is required to early assess the neurological status and to maintain the cerebral oxygenation and metabolism within the normal physiological values which may be saved by sugammadex.

the aim of this study is to compare sugammadex versus neostigmine as a reversal to the neuromuscular blockade of rocuronium in patients undergoing supratentorial tumors resection. comparison will include hemodynamics, respiratory effort and degree of sedation. indicators of global cerebral oxygenation and haemodynamics will be calculated using jugular bulb and peripheral arterial blood sampling.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical class status i - iii . * patients scheduled for elective supratentorial brain tumor resection exclusion criteria: * severe uncompensated cardiac disease. * severe uncompensated respiratory disease. * severe uncompensated hepatic disease. * severe uncompensated renal disease. * morbidly obese patients. * documented hypersensitivity to one of the used drugs. * surgery in sitting position * surgery in prone position * patients with altered level of consciousness. * pregnancy.
a phase i/ii study of mis-matched immune cells (allostim) in patients with advanced hematological malignancy

Conditions: Hematological Malignancy; Leukemia; Lymphoma; Multiple Myeloma

Summary: the purpose of this study is to determine the safety and anti-tumor effects of an experimental immunotherapy drug, called allostim, which is intentionally mis-matched immune cells which are designed to elicit the same anti-tumor mechanism that occurs in allogeneic bone marrow/stem cell mini-transplant (bmt) procedures, without the toxicity associated with graft vs. host disease (gvhd).

allostim is combination biological drug and medical device formulation consisting of allogeneic immune cells that have been expanded and differentiated ex-vivo. these cells are conjugated to monoclonal antibody coated microparticles prior to infusion. the immune cells are living cd4+ memory th1-like t-cells (t-stim) that are differentiated from precursors purified from normal donor blood. allostim is a composition of t-stim cells conjugated to paramagnetic epoxy covered microparticles (4.5micron) with covalently bound anti-cd3/anti-cd28 monoclonal antibodies (dynabeads® clinexvivo™ cd3/cd28) at a 2:1 bead:cell ratio. the t-stim cells are intentionally mismatched to the recipient. the graft vs. tumor (gvt) effect that occurs after allogeneic bone marrow transplant (bmt) is a curative therapy for advanced hematological malignancy but the clinical application of gvt is severely limited by graft vs. host disease (gvhd) toxicity. allostim is designed to elicit the "mirror" of the gvt/gvhd effects in the host immune system. rather than trying to separate these effects, we have proposed that the effects could remain associated and "mirrored" onto the host immune system creating linked host vs. tumor (hvt) and host vs. graft (hvg) effects. we hypothesized that allogeneic th1 memory cells activated at time of infusion to produce type 1 cytokines and express cd40l would elicit hvt/hvg "mirror effects" in immunocompetent cancer patients.

Eligibility criteria:
inclusion criteria: * histologically confirmed hematological malignancy * unresponsive to chemotherapy and/or recurrence after autologous transplant * adequate kidney, liver, lung and heart function exclusion criteria: * prior allogeneic transplant * immunosuppressive therapy for concurrent medical condition * active viral infection

Keywords: non-hodgkins lymphoma hodgkins lymphoma acute lymphoblastic leukemia chronic myeloid leukemia chronic lymphocytic leukemia multiple myeloma immunotherapy allogeneic cell therapy
protons vs. photons for high-risk prostate cancer

Conditions: Prostate Cancer; Radiotherapy Side Effect

Summary: the purpose of this study is to assess late gastro-intestinal side-effects comparing proton therapy to photon therapy in high-risk prostate cancer patients receiving whole pelvic irradiation.

proton therapy (pt) is a radiation technique with possibility to spare normal pelvic organs: bladder, rectum and bowel for pc patients. most pc patients treated with pt receive pt to the prostate gland alone. with pt, we aim to examine pc patients in high risk with both lymph node and prostate treatment will experience less late side effects with pt compared to photon treatment. the investigators propose a national open-labelled phase iii randomized controlled trial (rct) of proton therapy versus photon therapy of the prostate including the regional elective ln for localized/locally advanced prostate cancer patients combined with androgen deprivation therapy (adt) aimed at 3 years. the investigators aim at reducing gastro-intestinal toxicity grad 2 more than 5 points, which is considered clinical significant, measured by mean expanded prostate cancer index composite-26 (epic-26) bowel scores at 24 months and improve hrqol. secondary endpoints include morbidity, quality of life and survival data up to 10 years after treatment.

Eligibility criteria:
inclusion criteria: * histologically verified localized/locally advanced prostate cancer t1-3bn0-1m0 (tnm 8th edition). a clinical t4 is allowed if it is because of invasion into the bladder neck. * adenocarcinoma (mixed histology allowed as long as the adenocarcinoma component comprise more than 50%) * indication for elective lymph node irradiation * psa \< 100 ng/ml * age ≥18 years * performance status 0-1 * life expectancy ≥ 10 years * able to understand and comply with the treatment protocol * no evidence of inflammatory bowel disease ability to adhere to procedures for study and follow-up * signed informed consent to participate in the study exclusion criteria: * no previous treatment for prostate cancer * hip-prostheses * other metal devices in the pelvic region (except fiducials) * previous major abdominal/rectal surgery * any other malignancy the last five years except for basal or squamous cell skin cancer * unable to understand patient information or comply with treatment and safety instructions * unable to read and understand patient information due to cognitive disabilities or language (danish).

Keywords: proton therapy high risk intensity modulated radiotherapy
paclitaxel, carboplatin and gemcitabine in the treatment of patients with advanced transitional cell cancer of the bladder

Conditions: Bladder Cancer

Summary: this trial will evaluate the efficacy and safety of combination chemotherapy (paclitaxel, carboplatin, and gemcitabine) prior to surgery in the treatment of patients with locally advanced transitional cell cancer of the bladder.

this is a phase ii trial of neoadjuvant chemotherapy with paclitaxel, carboplatin and gemcitabine in the treatment of locally advanced transitional cell carcinoma of the bladder. patients will be stratified based on extent of disease. patients with t3, n0 disease will receive 3 cycles of chemotherapy and then proceed to cystectomy. patients with t4 disease or any patient with n1-3 disease will receive 3 cycles of therapy followed by assessment of response. patients with evidence of response will then receive an additional three cycles of therapy with reassessment of resectability after cycles #6. correlative studies: tumor specimens obtained at initial biopsy will be assayed for expression of p53, rb and p21.

Eligibility criteria:
inclusion criteria: * patients must have histologically proven locally advanced (t3-4, n0 or tany, n1-3) urothelial carcinoma of the bladder. patients with local disease and unilateral or bilateral hydronephrosis will be eligible and included in the t3 arm of the study. * tumor specimens must be available for assay of molecular markers. * ecog (eastern cooperative oncology group) performance status of 0 or 2 (a measure of general well being where 0 is asymptomatic and 5 is death) * life expectancy of 12 weeks or more * adequate bone marrow, renal and hepatic function exclusion criteria: * patients may not have had prior systemic or intra-arterial chemotherapy and no prior radiotherapy (patients may have received intravesicular chemotherapy). * evidence of distant metastasis * unresolved bacterial infection

Keywords: neoadjuvant chemotherapy
artificial intelligence as a decision making tool in neurology

Conditions: Clinical Decision-making; Medical Reporting; Neurological Diseases or Conditions; Emergency Department Visit

Summary: background: the establishment of neuroinformatics as a distinct field has enabled the integration of computational biology and informatics to improve neurological research. this interdisciplinary approach enhances the capacity to integrate diverse datasets, unravel complex neural networks, and develop computational models that can improve clinical management. the investigators aim to evaluate whether an artificial-intelligence-based tool is effective in non-english-speaking regions. hypothesis: integrating a language model-based clinical assistance system within the neurology ward will significantly enhance the efficiency and accuracy of patient care by leveraging neuroinformatics principles. the investigators hypothesize that combining natural language processing and data analytics will improve diagnostic and treatment processes.

research design: a pre-post-intervention design will be used, measuring outcomes before and after the implementation of a neuroinformatics-driven clinical assistance system. changes in diagnostic accuracy, treatment decisions, and workflow efficiency will be quantified. workflow: 1. a neurologist evaluates each patient, and the patient signs informed consent. 2. a medical student manually uploads de-identified clinical information to a secure interface. 3. data are analyzed by a large language model (llm) system through a hospital-approved application. 4. a senior physician must approve any decision based on the llm's recommendation. 5. for half of the prospectively enrolled participants, the llm's recommendation is presented to the resident. retrospective data: 1. the investigators will extract data from 10,000 patients who were evaluated by a neurologist in the emergency department. 2. clinical information (without patient identifiers) will be uploaded to a secure, hospital-approved llm with a security key. 3. the model's output will be compared with actual clinical decisions and patient outcomes (e.g., mortality, discharge status).

Eligibility criteria:
inclusion criteria: * informed consent exclusion criteria: * unable to give informed consent
hypofractionated vs. conventionally fractionated concurrent crt for unresectable stage iii nsclc

Conditions: Unresectable Stage III Non-small-cell Lung Cancer

Summary: this protocol is a phase iii randomized controlled trial (rct) evaluating the efficacy of hypofractionated vs. conventionally fractionated concurrent chemo-radiotherapy for unresectable stage iii non-small-cell lung cancer

hypofractionated radiotherapy (rt) delivers higher doses of rt over a shorter period of time and may kill more tumor cells and may have fewer side effects. dose escalation in unresectable stage iii nsclc has been safely achieved up to level 3 (ptv-g60.5gy/22fx, 2.75gy/fx; ptv-c 49.5gy/22fx, 2.25gy/fx). acute toxicities were well tolerable. further stage ii clinical study has found that hypofractionated rt can significantly improve the efficacy of patients with a low toxicity profile. the aim of this study is to compared with hypofractionated and conventionally fractionated concurrent chemotherapy , and evaluate whether hypofractionated rt can improve local control and overall survival in unresectable stage iii non-small-cell lung cancer (nsclc).

Eligibility criteria:
inclusion criteria: * male or female, aged 18 years to 75 years •.histologically proven lung adenocarcinoma or squamous cell lung carcinoma of r unresectable stage iii nsclc(according to the tnm classification in theunion for international cancer control (uicc) 7th ed.) * no prior epidermal growth factor receptor tyrosine kinase inhibitors (egfr-tkis) treatment or other targeted therapy * no prior thoracic rt * no severe perioperative complications and expected postoperative lifespan ≥4 months * ecog performance status 0-1 * voluntarily participated in this study and signed the informed consent form by himself or his agent. had good compliance with the study procedures, and can cooperate with the relevant examination, treatment and follow-up exclusion criteria: * diagnosed with other prior or concurrent malignancies (neoplasm) except for basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years * patients with any severe or uncontrolled systematic disease including severe cardiovascular, liver, kidney, hematopoietic, metabolic disease, or uncontrolled active infection that would preclude study participation * patients with positive mental disorder that would preclude study participation; * contradictory to chest radiotherapy * pregnant or nursing women * concurrent other anti-cancer treatment * prior epidermal growth factor receptor tyrosine kinase inhibitors (egfr-tkis) treatment or other targeted therapy
binge focused therapy: a guided, self-help, group-based approach for binge eating disorder

Conditions: Binge-Eating Disorder; Eating Disorder

Summary: the "brain over binge recovery guide" (hansen, 2016), is a self-help approach that incorporates fundamental aspects of acceptance and commitment therapy, dialectical behavioural therapy, motivational enhancement therapy and addictions treatment. this approach has been streamlined into a guided self-help protocol (binge focused therapy, or bft) that can be delivered by undergraduate students with minimal mental health experience in 3 group sessions spread over 8 weeks (i.e., week 1, week 2, week 8). the aim of this proof-of-concept study is to provide preliminary data to examine whether this approach is feasible and has clinical potential for patients with binge eating disorder.


Eligibility criteria:
inclusion criteria: * age 18 years or older; * meets dsm-5 criteria for moderate to severe binge eating disorder (bed) as determined through screening interview by an eating disorder psychiatrist and validated with the eating disorder diagnostic scale (a self-report screening tool); * provides written informed consent. exclusion criteria: * currently receiving treatment for bed; * is taking a psychotropic medication (e.g., antidepressant, stimulant, etc.) and the dose has been changed 2 weeks prior to baseline; * insufficient knowledge of english.

Keywords: guided self-help group-based intervention binge focused therapy brain over binge non-expert guided minimally intensive
emisep : early spinal cord lesions and late disability in relapsing remitting multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to evaluate the prognostic value of early focal lesions and early diffuse lesions on ambulatory disability progression within 5 years after clinical onset.

prospective, multicentric study

Eligibility criteria:
patients with multiple sclerosis: inclusion criteria: * relapsing remitting multiple sclerosis patients (mac donald 2010 criteria) * first clinical event \< 1 year * brain mri \> 9 lesions or/and spinal cord attack with focal lesion on spinal cord mri * score expended disability status scale \< 3 * age between 18 and 40 years exclusion criteria: * multiple sclerosis progressive * patients treated with immunosuppressive therapy * pregnancy healthy volunteers: inclusion criteria: -age between 18 and 40 years exclusion criteria: -pregnancy

Keywords: multiple sclerosis spinal cord mri longitudinal study disability
treatment of peripheral t-cell lymphoma

Conditions: Peripheral T-cell Lymphoma

Summary: the purpose of this study is to evaluate the efficacy and safety of gdpt regiment (gemcitabine，cisplatin,prednisone ,thalidomide ) for patients with peripheral t-cell lymphoma.

patients with peripheral t-cell lymphoma usually have a bad prognosis. these patients cannot be treated successfully with the conventional chemotherapy of chop. the investigators have been proceeding this trial to evaluate the efficacy and safety of the combination chemotherapy regiment gdpt regiment (gemcitabine，cisplatin,prednisone ,thalidomide ) in the patients with peripheral t-cell lymphoma.

Eligibility criteria:
inclusion criteria: age range 14-70 years old; ecog performance status 0-2; estimated survival time \> 3 months histological confirmed peripheral t cell lymphoma none of chemotherapy or radiotherapy has been previously used none of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/l, platelet ≥ 100×109/l, alt and ast ≤ 2×uln, serum bilirubin ≤ 1.5×uln, serum creatine ≤ 1.5×upper limitation of normal (uln), serum albumin ≥ 30g/l, serum plasminogen is normal (inclusion criteria of 1,3,6 groups ) at least one measurable lesion none of other serious diseases, cardiopulmonary function is normal pregnancy test of women at reproductive age must be negative patients could be followed up none of other relative treatments including the traditional chinese medicine, immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic treatments. volunteers who signed informed consent. exclusion criteria: disagreement on blood sample collection patients allergic of any of drug in this regimen or with metabolic disorder pregnant or lactating women serious medical illness likely to interfere with participation serious infection primitive or secondary tumors of central nervous system chemotherapy or radiotherapy contraindication the evidence of cns metastasis history of peripheral nervous disorder or dysphrenia patients participating in other clinical trials patients taking other antitumor drugs patients estimated to be unsuitable by investigato

Keywords: peripheral t-cell lymphoma;chemotherapy; rr;pfs;os